Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aura Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AURA
Nasdaq
8731
https://aurabiosciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aura Biosciences Inc
We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate
- Mar 28th, 2024 10:12 am
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Mar 27th, 2024 11:00 am
11 Oversold Biotech Stocks To Buy Right Now
- Mar 17th, 2024 9:20 pm
Aura Biosciences to Participate in Upcoming Investor Conferences
- Feb 26th, 2024 12:00 pm
Owning 48% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA),
- Jan 7th, 2024 12:55 pm
Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet
- Dec 11th, 2023 2:55 pm
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
- Dec 7th, 2023 1:00 pm
Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade
- Nov 23rd, 2023 2:55 pm
David Johnson Bought 232% More Shares In Aura Biosciences
- Nov 12th, 2023 12:06 pm
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
- Nov 9th, 2023 9:05 pm
Aura Biosciences Announces Pricing of Public Offering of Common Stock
- Nov 7th, 2023 3:02 am
Aura Biosciences Announces Proposed Public Offering of Common Stock
- Nov 6th, 2023 9:08 pm
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
- Nov 6th, 2023 8:00 pm
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
- Oct 31st, 2023 8:05 pm
Aura Biosciences Independent Chairman of the Board Acquires 30% More Stock
- Oct 8th, 2023 12:17 pm
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
- Oct 2nd, 2023 8:05 pm
Here's Why We're Not Too Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Situation
- Aug 28th, 2023 11:40 am
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
- Aug 9th, 2023 11:00 am
Owning 38% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA),
- Jul 31st, 2023 10:07 am
Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
- May 12th, 2023 11:00 am
Scroll